Archive
544 articles, sorted by publication time.
A seemingly technical drug-pricing payment design is now affecting the daily operations of America’s safety-net health care system; for hospitals with limited resources, a delayed discount may be the difference between whether pharmacies, clinics, and hospital beds can hold on.
The hardest step in moving a new drug idea from the laboratory into human trials is often not imagination, but clinical design, regulatory pathways, and resource allocation. Parexel’s new platform reflects how the CRO industry is pushing the boundaries of its services into earlier-stage R&D.
The significance of this publication is not that it claims to replace human trials, but that it brings organ chips back to one of the most expensive questions in new drug development: whether drug exposure observed in the laboratory can point earlier and more reliably to clinical outcomes.
Moving from a laboratory concept to human trials, the real hurdle for cancer vaccines is not how novel the technical terminology is, but whether immune responses can be translated into measurable and reproducible clinical benefit.
Market technicals are beginning to reassess the biotech sector, but a price rebound does not mean R&D risks have disappeared. For investors and industry observers, the real question is not whether they can chase the next market move, but how to identify which companies can withstand the successive tests of clinical development, funding, and regulation.
Near-dramatic tumor regression in mouse experiments pushed a pancreatic cancer study to the threshold of human trials; but the paper’s retraction and controversy over conflict-of-interest disclosures also underscore that medical breakthroughs must withstand both scientific and ethical scrutiny.
Interest rates, M&A, and clinical readouts have given biotech stocks room for renewed imagination; but for small drugmakers, a long and expensive road of validation still separates a market rebound from medical progress.
A capital raise of up to AU$37.5 million will not rewrite the landscape of cancer diagnostics, but it marks an early-stage biotech company’s entry into a more expensive clinical phase that is also better able to distinguish the strength of the science.
As clinical science needs more time to prove itself while markets demand faster capital exits, the biotech industry is recalculating the order of risks around listings, mergers and acquisitions, and regulation.
HHS and the FDA have launched clinical trial reforms that, on the surface, aim to shorten IND and late-stage trial processes; at a deeper level, they respond to U.S. anxiety over early human data and investment flows after the rise of China’s biotech sector.
Insilico Medicine and SK Biopharmaceuticals are directing their collaboration toward neuroimmune diseases, with a striking upper limit on deal value; but these diseases span the brain, immunity, and clinical subtyping, and real progress will still depend on whether targets can be supported by human evidence.
Licensing and investment partnerships between U.S. drugmakers and Chinese biotech companies are moving from commercial judgment toward the boundary of national security review; if a new draft bill advances, the division of labor in global new drug development may also be repriced.